// App-Quantinova.ai

311 : A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

Researchers

Presenter

  • Milind M. Javle

Principal Investigators

  • John A. Bridgewater

  • Olumide B. Gbolahan

  • Christiane Jungels

  • May Thet Cho

  • Kyriakos P. Papadopoulos

  • Fiona C. Thistlethwaite

  • Jean-Luc Re Canon

  • Lulu Cheng

  • Sonia Ioannidis

  • Sven Gogov

  • Aung Naing

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • University of Alabama at Birmingham, Birmingham, AL

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • University of California, Davis Comprehensive Cancer Center, Sacramento, CA

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Department of Oncology-Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium

  • Incyte Corporation, Wilmington, DE

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • United Kingdom

  • Belgium

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Open Label

  • Simon'S Two Stage Design

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved